Session 2: Advances in Psychopharmacotherapy and Therapeutic Neuromodulation (July 24-28)
This course will review the concepts of evidence-based and measurement-based care and use them to develop optimal treatment strategies for major psychiatric disorders. Participants will recognize the significant number of patients who are insufficiently responsive to initial therapeutic interventions and will utilize available biological treatments optimally, including the first and second generation antipsychotics, antidepressants, mood stabilizing agents, anxiolytic/sedative hypnotics, and therapeutic neuromodulation. Participants will also develop treatment strategies based on the results of randomized-controlled and pragmatic trials tempered by the realities of clinical practice, and incorporate clinically relevant issues related to drug therapy including pharmacokinetics, pharmacodynamics, and drug interactions.
Monday Introduction; Treatment of high risk, prodromal, first-onset, early course, and multi-episode patients; Results from pilot studies of novel therapies, randomized controlled, and pragmatic trials
Tuesday Review recent changes in diagnosis and treatment of depressive disorders
Wednesday Review the concept of therapeutic neuromodulation including electroconvulsive therapy, vagus nerve stimulation, transcranial magnetic stimulation, and deep brain stimulation
Thursday Diagnosis and treatment of bipolar disorder; Results of STEP-BD trial; Diagnosis and drug therapy of neurocognitive disorders; Clinical implications of CATIE Alzheimer’s Disease trial results
Friday Opioid training: Diagnosis and management of opioid use disorders, problems regarding patient adherence to treatment, strategies to improve adherence
Accreditation and Designation of Credit:
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Medical College of Wisconsin designates this live activity for a maximum of 15 AMA PRA Category 1 Creditstm. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical College of Wisconsin designates this activity for up to 15 hours of participation for continuing education for allied health professionals.
The Medical College of Wisconsin is approved by the American Psychological Association to sponsor continuing education for psychologists. MCW maintains responsibility for this program and its content.
This activity contains content or processes that may be potentially stressful.
The Medical College of Wisconsin is registered with the Illinois Department of Professional Regulation as a Continuing Education Sponsor for social workers (license number 159-000664).
Application for CME credit has been filed with the American Academy of Family Physicians. Determination of credit is pending.
Tuition includes course materials and continental breakfast.
Purchase an additional 5 DAY session and receive a $100.00 discount. Use coupon code: +DCSI
Please note: A $10.00 non-refundable processing fee is assessed on registrations.
This advanced seminar is geared to mental health and health professionals.
(1) Compare the role of evidence-based and measurement-based care in the development and use of treatment strategies for major psychiatric disorders
(2) Consider the relative value of various psychotropic agents for the treatment of major psychiatric disorders
(3) Discuss the emerging role of therapeutic neuromodulation in the treatment of psychiatric disorders
(4) Underscore the importance of developing strategies which enhance patient adherence to treatment
(5) Consider strategies for the proper diagnosis and treatment of opioid use disorders
Philip Janicak, MD, is the Director of the Transcranial Magnetic Stimulation Center and Consultant, Linden Oaks Medical Group at Edward-Elmhurst Healthcare; Adjunct Professor, Department of Psychiatry and Behavioral Sciences, North-western University Feinberg School of Medicine; and APA Distinguished Life Fellow. Dr. Janicak’s primary research interests are the assessment and treatment of mood and psychotic disorders. He has conducted several clinical trials, most recently deep transcranial magnetic stimulation for major depression, maintenance of acute TMS antidepressive effects over one year, and lurasidone plus cognitive remediation for schizophrenia. He has been an NIMH grant awardee as both principal and co-investigator. He has authored, co-authored, or edited over 500 publications and is first author of Principles and Practice of Psychopharmacotherapy
Dr. Janicak has the following disclosure: Otsuka and Neuronetics: Speaker and Consultant honorarium.
In accordance with the ACCME® standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.
- 15.00 AAFPAAFP credit.
- 15.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 15.00 APAAPA credit.
- 15.00 Hours of ParticipationHours of Participation credit.